Literature DB >> 18246407

Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings.

Benedetto Falsini1, Lucia Ziccardi, Ilaria Lazzareschi, Antonio Ruggiero, Luca Placentino, Anna Dickmann, Lucia Liotti, Marco Piccardi, Emilio Balestrazzi, Cesare Colosimo, Concezio Di Rocco, Riccardo Riccardi.   

Abstract

The aim of this study was to evaluate longitudinally functional and neuro-radiologic findings in childhood optic gliomas (OG), by comparing flicker visual evoked potentials (F-VEPs) with brain magnetic resonance imaging (MRI) changes. Fourteen children (age range: 1-13 years) with OGs underwent serial F-VEP, MRI and neuro-ophthalmic examinations over a 38 month (median, range: 6-76) follow-up. F-VEPs were elicited by 8 Hz sine-wave flicker stimuli presented in a mini-Ganzfeld. Contrast-enhanced MRI examinations were performed. Results of both tests were blindly assessed by independent evaluators. F-VEPs were judged to be improved, stable or worsened if changes in the amplitude and/or phase angle of the response exceeded the limits of test-retest variability (+/-90th percentile) established for the same patients. MRI results were judged to show regression, stabilization or progression of OG based on its changes in size (+/-20%) or extension. Two to seven pairs of F-VEP/MRI examinations per patient (median: 4) were collected. Based on a total of 38 pairs of F-VEP/MRI examinations, both tests agreed in showing worsening (progression), stabilization and improvement (regression) in 5, 15 and 10 cases, respectively. In 3 cases, F-VEPs showed a worsening and MRI a stabilization, while in 5 cases F-VEPs showed an improvement and MRI a stabilization. Agreement between F-VEP and MRI changes was 78.9% (95% CI: +/- 37%, K statistics = 0.67, P < 0.001). The results indicate that longitudinal F-VEP changes can predict changes in MRI-assessed OG size and extension, providing a non-invasive functional assay, complementary to neuro-imaging, for OG follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18246407     DOI: 10.1007/s11060-008-9537-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

Review 1.  Neurofibromatosis type 1 in childhood.

Authors:  R Listernick; J Charrow
Journal:  J Pediatr       Date:  1990-06       Impact factor: 4.406

2.  Visual evoked potentials in chiasmal gliomas in four adults.

Authors:  M J Kupersmith; I M Siegel; R E Carr; J Ransohoff; E Flamm; E Shakin
Journal:  Arch Neurol       Date:  1981-06

3.  Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging.

Authors:  C F Parsa; C S Hoyt; R L Lesser; J M Weinstein; C M Strother; R Muci-Mendoza; M Ramella; R S Manor; W A Fletcher; M X Repka; J A Garrity; R N Ebner; M L Monteiro; R M McFadzean; I V Rubtsova; W F Hoyt
Journal:  Arch Ophthalmol       Date:  2001-04

4.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Authors:  L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

5.  Optic nerve glioma and the management of optic nerve tumours in the young.

Authors:  J E Wright; A A McNab; W I McDonald
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

6.  Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

Authors:  R Listernick; D N Louis; R J Packer; D H Gutmann
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

7.  Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.

Authors:  R J Packer; B Lange; J Ater; H S Nicholson; J Allen; R Walker; M Prados; R Jakacki; G Reaman; M N Needles
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

8.  von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata.

Authors:  R A Lewis; L P Gerson; K A Axelson; V M Riccardi; R P Whitford
Journal:  Ophthalmology       Date:  1984-08       Impact factor: 12.079

9.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; M J Greenwald; N B Esterly
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

10.  The value of visual evoked potential as a screening test in neurofibromatosis.

Authors:  B Jabbari; C G Maitland; L M Morris; J Morales; C H Gunderson
Journal:  Arch Neurol       Date:  1985-11
View more
  8 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

Review 2.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

Review 3.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

4.  Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.

Authors:  Sarah Zakaib Rassi; Luis H Ospina; Ariane Bochereau; Yvan Samson; Sébastien Perreault; Dave Saint-Amour
Journal:  Doc Ophthalmol       Date:  2019-06-26       Impact factor: 2.379

5.  Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1.

Authors:  John P Kelly; Avery H Weiss
Journal:  Neuro Oncol       Date:  2013-10-06       Impact factor: 12.300

6.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

7.  Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.

Authors:  Balazs Hegedus; Frank W Hughes; Joel R Garbow; Scott Gianino; Debasish Banerjee; Keunyoung Kim; Mark H Ellisman; Milam A Brantley; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

Review 8.  Temozolomide and oral etoposide in children with recurrent malignant brain tumors.

Authors:  Antonio Ruggiero; Anna Ariano; Silvia Triarico; Michele Antonio Capozza; Alberto Romano; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà
Journal:  Drugs Context       Date:  2020-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.